Compare abrdn Income Credit Strategies Fund (ACP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs BioNTech SE - ADR — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while BioNTech SE - ADR trades at $93 (market cap $23.84B). The key difference: BioNTech SE - ADR is far larger — about 36.3× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ACP | BNTX | |
|---|---|---|
Market Cap | $656.21M | $23.84B |
Sector | Financials | Health |
52-Week High | $5.98 | $119.34 |
52-Week Low | $5.01 | $83.89 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $7.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
BioNTech (BNTX) trades at $94.29, down 3.34% on the day, as the company navigates its transition from COVID-19 vaccine dominance to oncology focus. The stock shows a bullish technical signal with strong analyst support (87.5% buy ratings) and a $130.83 consensus price target. However, fundamental challenges persist with negative net income margins (-44.64%) and declining revenues from pandemic peak levels, offset by a robust $16.78 billion cash position and ongoing $1 billion share repurchase program.
The outlook balances promising oncology pipeline developments against near-term profitability challenges. Investment opportunity lies in BioNTech's cash-rich balance sheet and advancing cancer therapeutics, while risks include execution uncertainty in the therapeutic transition, manufacturing restructuring costs, and competitive pressure in the oncology space. The stock presents a high-risk, high-reward proposition for investors betting on successful pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
